The US Food and Drug Administration (FDA) approved the first at-home test for syphilis for sale without a prescription. The test, manufactured by NOWDiagnostic and called First To Know Syphilis Test, arrives amid an 80% increase in cases in the US between 2018 and 2022, from 115 000 to 207 000 cases.
Risultati per: Diagnosi, trattamento e follow-up del cancro alla vescica
Questo è quello che abbiamo trovato per te
Percorsi personalizzati contro il cancro legati al gene BRCA
Nuova opzione di trattamento per la sclerosi multipla
Cancro al seno, l'IA svela chi lo svilupperà dalle mammografie
Accuratezza pari o maggiore dei calcolatori in uso
Shortfalls in Follow-up Albuminuria Quantification After an Abnormal Result on a Urine Protein Dipstick Test
Annals of Internal Medicine, Ahead of Print.
Shortfalls in Follow-up Albuminuria Quantification After an Abnormal Result on a Urine Protein Dipstick Test
Annals of Internal Medicine, Ahead of Print.
Symptom-Triggered Testing Speeds Up Diagnosis of Aggressive Ovarian Cancer
Symptoms such as abdominal bloating and pain have been a signal to UK and US clinicians to perform diagnostic tests for ovarian cancer. If the results are abnormal, patients in the UK may be fast-tracked for a referral within 2 weeks, despite a lack of clear evidence on how effective this is for women with aggressive ovarian cancer.
Role of Clinician Specialty in Picking Up PrEP
HIV prevention remains a major public health challenge. In 2019, after years of new HIV diagnoses hovering around 38 000 individuals in the US per year, agencies across the US Department of Health and Human Services developed the Ending the HIV Epidemic in the US plan to reduce new HIV diagnoses by 90% by 2030. With setbacks from converging pandemics, in 2021 new infections hovered at 36 000. Thus, finding ways to optimize HIV prevention, including strategies such as pre-exposure prophylaxis (PrEP), is urgent.
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up
Circulation, Volume 150, Issue 14, Page 1151-1153, October 1, 2024.
Tumori al seno, diagnosi in ritardo per il 20% delle immigrate. Il 39% non esegue la mammografia
Per l’86% degli oncologi sono troppe le disparità di accesso alle cure
Tumori al seno, diagnosi in ritardo per il 20% delle immigrate
Per 86% oncologi sono troppe le disparità di accesso alle cure
Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator Through Long-Term Follow-Up: Final Results From the Pivotal Study
Circulation, Ahead of Print. Background: Substernal lead placement of the extravascular implantable cardioverter-defibrillator (EV ICD) permits both defibrillation at thresholds similar to those seen with transvenous ICDs and effective antitachycardia pacing (ATP), while avoiding the vasculature and associated complications. The global Pivotal study has shown the EV ICD system to be safe and effective through 6 months, but long-term experience has yet to be published. We aim to report the performance and safety of the EV ICD system throughout the study.Methods: The EV ICD Pivotal study was a prospective, global, single-arm, pre-market clinical study. Individuals with a class I or IIa indication for a single-chamber ICD per guidelines were enrolled. Freedom from major system- or procedure-related complications, as well as appropriate and inappropriate therapy rates, were assessed through 3 years using the Kaplan-Meier method. Anti-tachycardia pacing success was calculated using simple proportions.Results: An implant was attempted in 316 patients [25.3% female, 53.8±13.1 years old, 81.6% primary prevention, LVEF 38.9%±15.4%]. Of 299 patients with a successful implant, 24 experienced 82 spontaneous arrhythmic episodes that were appropriately treated with either ATP only (38, 46.3%), shock only (34, 41.5%), or both (10, 12.2%) for a Kaplan-Meier-estimated rate of first any appropriate therapy of 9.2% at 3 years. Antitachycardia pacing was successful in 77.1% (37/48) of episodes, and ATP usage significantly increased from discharge to last follow-up visit (P
La regina di Spagna a Milano per la ricerca contro il cancro
Visita all’Istituto di oncologia molecolare di Fondazione Airc
L'infertilità non è una colpa, i consigli per affrontare la diagnosi
Il 22 settembre si celebra la Giornata nazionale di informazione
Diagnosi di Alzheimer: dai biomarcatori di resilienza all’analisi del linguaggio
La ricerca sulla comprensione e sulla gestione di questa malattia neurodegenerativa si apre ai fattori di protezione e allo screening con l’intelligenza artificiale
Interventions to Increase Follow-Up of Abnormal Stool-Based Colorectal Cancer Screening Tests in Safety Net Settings: A Systematic Review
Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States. Despite evidence that screening effectively reduces incidence and mortality, screening is suboptimal, especially in safety net healthcare systems and federally qualified health centers (FQHCs). Safety net healthcare systems represent 25% of U.S. hospitals and are defined as hospitals that organize and deliver a significant level of healthcare and other related services to individuals without insurance, receiving Medicaid, and other vulnerable patients.